December 15th, 2015

Company Update (NASDAQ:BIIB): Here’s who’s getting rich off of Biogen Idec’s success

[at bizjournals.com] – The news reported by Biogen Idec regarding its potential drug for Alzheimer’s may or may not turn out to benefit all of humankind many years down the road, but the . . . → Read More: Company Update (NASDAQ:BIIB): Here’s who’s getting rich off of Biogen Idec’s success Similar Articles: Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX® Pediatric Study Market Update (NASDAQ:BIIB): Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting Stock Update (NASDAQ:BIIB): Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.